Weight loss drug may kill 80% risk of diabetes


Including a specific weight loss drug along with diet and exercise may cut down the risk of diabetes by 80 per cent in people diagnosed with obesity and prediabetes, a study reported.

The results of the international clinical trial showed that liraglutide boosts weight loss by interacting with the areas of the brain which are responsible for controlling appetite and energy intake.

How world’s heaviest people fared after undergoing weight loss surgery

The findings were published in journal The Lancet, the results revealed that three years of uninterrupted treatment with once-daily liraglutide 3.0 mg, along with diet and increased physical exercise, eliminates the risk of developing Type 2 diabetes.

In reality, 60 per cent of those patients diagnosed with borderline diabetes the condition was reversed, and patients were back to healthy blood sugar levels, the study revealed.

Liraglutide helps in weight loss by activating specific portions of the brain areas that control appetite and eating, so that person feels fuller soon after the meals and their food intake is decreased,” said Carel le Roux, Professor at Imperial College London.

As liraglutide’s role in weight loss is very popular, this is for the first time it has been shown to basically reverse prediabetes and forbid diabetes, possible with the help of diet and exercise,” le Roux added.

Other patients who did go on to develop diabetes, those who were given liraglutide, took almost three times longer to develop the disease. Apart from this, liraglutide also assisted patients in losing 7 per cent body weight compared to just two per cent in the placebo group, the researchers said.

Liraglutide 3.0 mg a new therapeutic approach can really help patients suffering from obesity and prediabetes,” elaborated John Wilding, Professor at the University of Liverpool.

For conducting the trial experiment, the team followed 2,254 adults with prediabetes at 191 research sites in 27 countries globally.

The participants have randomly given either liraglutide 3.0 mg or a placebo delivered by injection below the skin per day for 160 weeks.

They were also given low-calorie diet and were advised to increase their physical activity.